Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Kissei/JCR’s Nesp Biosimilar Shows Equivalence in Japan PIII
January 18, 2018
- Life Science Institute Launches Clinical Study of IV Regenerative Medicine Product for Acute Myocardial Infarction
January 18, 2018
- Kyowa Kirin Officially Announces Launch of Japan’s 1st Rituxan Biosimilar on Jan. 18
January 18, 2018
- Mitsubishi Tanabe Grabs Add’l Indication for Novastan in China
January 17, 2018
- Toray Grants China License for Remitch OD to 3SBio
January 17, 2018
- Nichi-Iko Teams Up with 2 Philippine Companies
January 17, 2018
- Ethical Drug Sales Up 0.8% in November on Cancer Meds
January 17, 2018
- Nissui Pharmaceutical Invests 50 Million Yen in Regenerative Medicine Startup
January 16, 2018
- Repatha Auto Mini Doser Now Available in Japan
January 16, 2018
- Opdivo-Yervoy Combo Filed for RCC in Japan
January 16, 2018
- Japan’s 1st Rituxan Biosimilar to Hit Shelves as Scheduled despite Patent Suit Filed
January 16, 2018
- Janssen, NCNP Link Arms to Develop Biomarkers for Predicting Schizophrenia Risk
January 16, 2018
- JT/Torii’s JAK Inhibitor Delivers Positive PIII Data
January 15, 2018
- Takecab Most Promoted Drug for Hospital Doctors for 12 Months on End
January 15, 2018
- Eisai’s Oral Solid Dose Facility Completed in China
January 12, 2018
- Nippon Chemiphar’s Antidepressant Candidate Selected for AMED’s CiCLE Grant Program
January 12, 2018
- Suglat Filed for Type 1 Diabetes in Japan: Astellas/Kotobuki
January 12, 2018
- Will Symbicort and Adoair Face Generic Entries This Year? Trade Group Has Seen High Hurdle for Inhaler Drugs
January 11, 2018
- DeNA in AI Joint Research Pact with Asahi Kasei, Shionogi
January 11, 2018
- Shionogi Gains Access to US Startup’s Drug Discovery Platform
January 11, 2018
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…